All posts related to "psoriasis"

Demande de rétroaction de patients sur le brodalumab dans le traitement du psoriasis en plaques, de modéré à sévère

Stickman with megaphone calling for patient inputDemande de rétroaction de patients sur le brodalumab dans le traitement du psoriasis en plaques, de modéré à sévère

Souffrez-vous de psoriasis en plaques de modéré à sévère ? Vos commentaires seraient précieux.

Le programme commun d’évaluation des médicaments (PCEM) invite actuellement les patients et leurs fournisseurs de soins à faire parvenir aux organismes représentant les patients leurs suggestions et commentaires sur la présentation par le fabricant du brodalumab dans le traitement du psoriasis en plaques, de modéré à sévère.

Le PCEM fait partie de l’Agence canadienne des médicaments et des technologies de la santé. Le PCEM examine avec objectivité et rigueur l’efficacité et la rentabilité des médicaments et fournit des recommandations aux régimes d’assurance-médicaments publics du Canada (à l’exception du Québec) quant à leur inscription sur la liste des médicaments assurés.

Afin de l’aider dans son processus de recommandation, le PCEM accepte la rétroaction de groupe de patients comme le comité ACE (Arthritis Consumer Experts). Parce que la rétroaction de patients est essentielle à la prise de décision du gouvernement sur les médicaments, nous désirons recueillir vos commentaires pour communication au PCEM.

Voici l’information que recherche le PCEM dans ce dossier particulier : Continue reading

Call for patient input on brodalumab for moderate to severe plaque psoriasis

Stickman with megaphone calling for patient inputDo you have moderate to severe plaque psoriasis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for brodalumab for moderate to severe plaque psoriasis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Avis à l’intention des membres du comité ACE atteints de psoriasis et d’arthrite psoriasique :

An image of PureCare Herbal CreamSanté Canada a publié un avis de sécurité à propos des ingrédients qui entrent dans la composition de la crème à base de plantes PureCare.

La crème à base de plantes PureCare, commercialisée comme un traitement naturel contre l’eczéma et le psoriasis chez les enfants et les bébés, peut poser de graves risques pour la santé.

Les analyses du Ministère ont confirmé la présence dans ce produit d’un stéroïde d’ordonnance (propionate de clobétasol) et d’un autre ingrédient (phénoxyéthanol) non déclarés sur l’étiquette. Ces ingrédients peuvent avoir des effets sur la santé allant de l’irritation cutanée et de la déshydratation jusqu’à une hausse de la tension artérielle. Continue reading

Attention ACE members with psoriatic arthritis and psoriasis

An image of PureCare Herbal CreamHealth Canada has issued a warning about ingredients in PureCare Herbal Cream 

PureCare Herbal Cream, advertised as a natural treatment for eczema and psoriasis in children and babies, may pose serious health risks.

Health Canada testing confirmed the presence of a prescription steroid (clobetasol propionate) and another ingredient (phenoxylethanol) not declared on the product label. These ingredients may cause health effects ranging from skin irritation and dehydration to increased blood pressure. Continue reading

Demande de rétroaction d’organisations de patients sur l’utilisation du secukinumab dans le traitement du psoriasis en plaques de modéré à sévère

Megaphone GraphicSouffrez-vous de psoriasis en plaques de modéré à sévère ou prodiguez-vous des soins à quelqu’un qui en souffre ? Vos commentaires seraient précieux.

Le Programme commun d’évaluation des médicaments (PCEM) invite actuellement les patients et leurs fournisseurs de soins à faire parvenir aux organismes représentant les patients leurs suggestions et commentaires sur la présentation par le fabricant du secukinumab dans le traitement du psoriasis en plaques, de modéré à sévère. Son utilisation n’ayant pas encore été approuvée par Santé Canada, le médicament ne porte pas de nom de marque pour le moment. Toutefois, afin d’accélérer le processus d’examen, le PCEM demande la rétroaction d’organisations de patients avant même l’obtention de l’approbation du médicament par Santé Canada. Administré par injection, le secukinumab est un anticorps monoclonal entièrement humain qui cible l’interleukine 17-a (il-17a), une protéine qui joue un rôle majeur dans le développement des maladies inflammatoires. Dans deux phases III des essais cliniques, le secukinumab a démontré son efficacité dans le traitement du psoriasis en plaques, tout en étant bien toléré. Continue reading

Call for patient organization input on secukinumab for moderate to severe plaque psoriasis

Megaphone GraphicDo you have moderate to severe plaque psoriasis or care for someone who does? If so, we need your valuable input.

The Common Drug Review (CDR) is now welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for secukinumab (the medication’s generic name) for the treatment of moderate to severe plaque psoriasis. This medication has not yet been approved for use by Health Canada and therefore does not have a brand name. However, the Common Drug Review, in an effort to speed up the review process, is calling for patient input prior to Health Canada’s approval. Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. In two phase III clinical trials, it has been shown to be effective and well tolerated for treating plaque psoriasis. Continue reading

Heart health for people with psoriasis: Blood pressure

Heart with stethoscope beside itPsoriatic arthritis is linked to the skin disease, psoriasis, which causes a scaly-type rash usually occurring on the elbows, knees, and scalp. Psoriasis is considered a significant risk factor for developing psoriatic arthritis – up to 30% of people diagnosed with psoriasis go on to develop psoriatic arthritis. A recent study shows that people with extensive psoriasis are likely to have hypertension that’s inadequately controlled. According to the study, cardiovascular risk in people with psoriasis and psoriatic arthritis is best assessed using carotid ultrasound.

Continue reading

Call for patient organization input on apremilast for moderate to severe plaque psoriasis

Megaphone GraphicCall for patient organization input on apremilast (Otezla®) for moderate to severe plaque psoriasis

Do you have moderate to severe plaque psoriasis or care for someone who does? If so, we need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for apremilast (Otezla®) for the treatment of moderate to severe plaque psoriasis. Apremilast is an oral, small-molecule compound, taken as one tablet twice a day. In phase II and III clinical trials it has been shown to be effective and well tolerated for treating plaque psoriasis. The medication works by inhibiting the action of phosphodiesterase-4 (PDE4). PDE4 is an enzyme found in immune cells.

Continue reading

Cell death may be the cause of inflammatory disease

Grim ReaperA team of researchers from the Walter and Eliza Hall Institute in Melbourne has determined that the cell death called necroptosis could be the cause of inflammatory disease like Crohn’s disease, rheumatoid arthritis and psoriasis.

A molecule called RIPK1 (receptor interacting protein kinase 1) is involved in necroptosis; researchers say this particular molecule is essential for survival by preventing uncontrolled inflammation. RIPK1 acts as the ‘gatekeeper’ between cell life and death; RIPK1 is essential for a cell’s decision to live or die, and in determining how to die. Continue reading

The results are in for psoriatic arthritis & psoriasis survey

MAPPThe Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey confirms psoriasis and psoriatic arthritis (PsA) are frequently under treated or not treated at all. MAPP is the first probability survey that looked at patients, regardless of whether they were under the care of a healthcare provider or member of a patient advocacy group, and also included the physician perspective. The survey interviewed 3,426 patients who were randomly selected via a telephone survey of 139,948 households in the United States, Canada, France, Germany, Italy, Spain, and the United Kingdom. It also interviewed a total of 781 physicians from North America and Europe. The survey explored the following: Continue reading